tirzepatide

News

Lilly fires a broadside at Novo Nordisk's obesity ambitions

Denmark's Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs

News

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine

News

Trial win sets up filings for Lilly's diabetes blockbuster h...

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate tirzepatide, setting up regulatory filings for a drug that the drugmaker thinks could be the lynch

News

Lilly surges on positive phase 3 readout from diabetes conte...

Eli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be vindicated, according to its first phase 3 trial readout.<

Lilly fires a broadside at Novo Nordisk's obesity ambitions

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Trial win sets up filings for Lilly's diabetes blockbuster h...

Lilly surges on positive phase 3 readout from diabetes conte...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

tirzepatide

Editor's Picks